Unmet Medical Needs Stocks
Biopharmaceutical innovators in this sector target refractory diseases and rare conditions where current standards of care are either non-existent or fundamentally inadequate. Revenue models hinge on achieving regulatory breakthroughs and securing orphan drug designations, which grant long-term market exclusivity and significant pricing power.
As of Oct 23, 2026, Unmet Medical Needs has 81 US-listed companies worth $318B combined. The median member moved +0.2% over the past week; MLTX led among the 25 largest at +24.1% and INSM trailed at -3.0%.
Companies in Unmet Medical Needs
- GILD – Gilead Sciences Inc, $193B
- INSM – Insmed Inc, $20.4B
- YPF – YPF Sociedad Anonima, $19.7B
- SMMT – Summit Therapeutics PLC, $12.3B
- KRYS – Krystal Biotech Inc, $9.6B
- PTGX – Protagonist Therapeutics Inc, $9B
- CYTK – Cytokinetics Inc, $8.5B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- KNSA – Kiniksa Pharmaceuticals Ltd, $6.3B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- ZLAB – Zai Lab Ltd, $2.7B
- VERA – Vera Therapeutics Inc, $2.2B
- PHVS – Pharvaris BV, $2.1B
- PVLA – Palvella Therapeutics, Inc, $1.7B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- CMPS – Compass Pathways Plc, $1.6B
- AAPG – Ascentage Pharma Group International, $1.4B
- KARD – Kardigan, Inc. Common Stock, $1.2B
- OPK – Opko Health Inc, $1.2B
- ARDX – Ardelyx Inc, $842M
- MLTX – MoonLake Immunotherapeutics, $813M
- CADL – Candel Therapeutics Inc, $709M
- ZVRA – Zevra Therapeutics Inc., $676M
- ABUS – Arbutus Biopharma Corp, $648M
- VALN – Valneva SE ADR, $527M
- DRUG – Bright Minds Biosciences Inc, $506M
- EPRX – Eupraxia Pharmaceuticals Inc. Common Stock, $493M
- OCS – Oculis Holding AG Ordinary shares, $461M
- OVID – Ovid Therapeutics Inc, $441M
- ENTX – Entera Bio Ltd, $435M
- SPRY – ARS Pharmaceuticals, Inc, $427M
- AGMB – AgomAb Therapeutics NV American Depositary Shares, $422M
- RZLT – Rezolute Inc, $396M
- FENC – Fennec Pharmaceuticals Inc, $358M
- CTNM – Contineum Therapeutics, Inc. Class A Common Stock, $266M
- CUVL – Clinuvel Pharmaceuticals Limited American Depositary Shares, $262M
- IMRX – Immuneering Corp, $255M
- IKT – Inhibikase Therapeutics Inc, $251M
- CABA – Cabaletta Bio Inc, $251M
- XFOR – X4 Pharmaceuticals Inc, $243M
- ZNTL – Zentalis Pharmaceuticals Llc, $209M
- YARW – Yarrow Bioscience Inc, $183M
- CNTN – Canton Strategic Holdings, Inc., $149M
- UNCY – Unicycive Therapeutics Inc, $92M
- RLYB – Rallybio Corp, $89.9M
- MNOV – MediciNova Inc, $73.8M
- NTRB – Nutriband Inc, $73.5M
- GOSS – Gossamer Bio Inc, $59.9M
- KLRS – Kalaris Therapeutics, Inc., $56.2M
- TENX – Tenax Therapeutics Inc, $50.9M
- LONA – LeonaBio, Inc., $49M
- TIL – Instil Bio Inc., $41.6M
- ABVC – ABVC Biopharma Inc, $26.7M
- ATOS – Atossa Genetics Inc, $24.3M
- KYNB – Kyntra Bio, Inc., $23.8M
- HIND – Vyome Holdings, Inc., $13.8M
- FEMY – Femasys Inc, $13.1M
- CNSY – Cerenome, Inc., $12.9M
- ANEB – Anebulo Pharmaceuticals Inc, $12.8M
- KPRX – Kiora Pharmaceuticals Inc, $10.9M
- BCLI – Brainstorm Cell Therapeutics Inc, $9.2M
- VTGN – VistaGen Therapeutics Inc, $8.9M
- CALC – CalciMedica, Inc. Common Stock, $8.7M
- FBLG – FibroBiologics, Inc. Common Stock, $8M
- NKGN – NKGen Biotech, Inc. Common Stock, $7.8M
- INM – InMed Pharmaceuticals Inc, $7.6M
- ACXP – Acurx Pharmaceuticals LLC, $7.2M
- RVPH – Reviva Pharmaceuticals Holdings Inc., $6.5M
- CELZ – Creative Medical Technology Holdings Inc, $6.4M
- KALA – Kala Pharmaceuticals Inc, $3.7M
- REVB – Revelation Biosciences Inc, $3.3M
- CMND – Clearmind Medicine Inc. Common Shares, $3.3M
- ARTL – Artelo Biosciences Inc, $1.4M
- LABT – Lakewood-Amedex Biotherapeutics Inc. Common Stock, $1.4M
- EVFM – Evofem Biosciences Inc, $980,722
- BDRX – Biodexa Pharmaceticals, $860,974
- SRNE – Sorrento Therape, $441,024
- CDT – Conduit Pharmaceuticals Inc., $209,159
- PXMD – PaxMedica Inc. Common Stock, $88,385
- SCPS – Scopus Biopharma Inc, $16,833